Acetylcholinesterase Inhibitors May Be Another Piece In Alzheimer's Jigsaw

March 05, 1999

(Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial)

Acetylcholinesterase inhibitors, such as tacrine and donepezil, which have been designed to boost the apparent chemical deficiency in the brain caused by Alzheimer's disease, are the most successful treatments to date. In this week's BMJ Professor Michael Rösler from Psychiatrische Universitätsklinik, Germany and colleagues report the finding of the first large trial of another acetylcholinesterase inhibitor used by patients suffering from Alzheimer's, in a mainly European population.

The authors' six month trial involved the drug rivastigmine and they found that it was effective in treating some of the symptoms of patients with mild or moderate Alzheimer's disease. The research team also discovered that the effects of rivastigmine seem to be dose dependent - those patients receiving a higher dose of the drug showed clinically relevant (and statistically significant) improvements.

Rösler et al draw attention to the gastrointestinal side-effects experienced by some patients (27 per cent of those taking the higher dose of rivastigmine discontinued treatment owing to adverse effects), but report that these effects were mild and short lived and only occurred after the dosage had been increased.

In an accompanying commentary, Dr Tony Bayer from the University of Wales College of Medicine writes that the research by Rösler et al provides another piece in the Alzheimer's jigsaw, but also reports some of the shortcomings of their study. Bayer says that the patients who participated in the trial were not typical of those generally seen by psychiatrists and geriatricians and he says that the absence of measures of the neuropsychiatric effect of the drug is "unfortunate". Bayer also reports that the study "....tells us nothing about the long term impact of acetylcholinesterase inhibitor treatment or the considerable human and economic costs of Alzheimer's disease."

Contact:

Professor Michael Rösler, Head, Sektion Gerontopsychiatric, Psychiatrische Universitätsklinik, Würzburg, Germany ENTER E-MAIL ADDRESS HEREroesler@rzbox.uni-wuerzburg.de

or

Dr Tony Bayer, Director, Memory Team, Department of Geriatric Medicine, University of Wales College of Medicine, Llandough Hospital, Penarth bayer@cf.ac.uk
-end-


BMJ

Related Disease Articles from Brightsurf:

CLCN6 identified as disease gene for a severe form of lysosomal neurodegenerative disease
A mutation in the CLCN6 gene is associated with a novel, particularly severe neurodegenerative disorder.

Cellular pathway of genetic heart disease similar to neurodegenerative disease
Research on a genetic heart disease has uncovered a new and unexpected mechanism for heart failure.

Mechanism linking gum disease to heart disease, other inflammatory conditions discovered
The link between periodontal (gum) disease and other inflammatory conditions such as heart disease and diabetes has long been established, but the mechanism behind that association has, until now, remained a mystery.

Potential link for Alzheimer's disease and common brain disease that mimics its symptoms
A new study by investigators from Brigham and Women's Hospital uncovered a group of closely related genes that may capture molecular links between Alzheimer's disease and Limbic-predominant Age-related TDP-43 Encephalopathy, or LATE, a recently recognized common brain disorder that can mimic Alzheimer's symptoms.

Antioxidant agent may prevent chronic kidney disease and Parkinson's disease
Researchers from Osaka University developed a novel dietary silicon-based antioxidant agent with renoprotective and neuroprotective effects.

Tools used to study human disease reveal coral disease risk factors
In a study published in Scientific Reports, a team of international researchers led by University of Hawai'i (UH) at Mānoa postdoctoral fellow Jamie Caldwell used a statistical technique typically employed in human epidemiology to determine the ecological risk factors affecting the prevalence of two coral diseases--growth anomalies, abnormalities like coral tumors, and white syndromes, infectious diseases similar to flesh eating bacteria.

Disease-aggravating mutation found in a mouse model of neonatal mitochondrial disease
The new mitochondrial DNA (mtDNA) variant drastically speeds up the disease progression in a mouse model of GRACILE syndrome.

Human longevity largest study of its kind shows early detection of disease & disease risks
Human Longevity, Inc. (HLI) announced the publication of a ground-breaking study in the journal Proceedings of the National Academy of Sciences (PNAS).

30-year study identifies need of disease-modifying therapies for maple syrup urine disease
A new study analyzes 30 years of patient data and details the clinical course of 184 individuals with genetically diverse forms of Maple Syrup Urine Disease (MSUD), which is among the most volatile and dangerous inherited metabolic disorders.

Long-dormant disease becomes most dominant foliar disease in New York onion crops
Until recently, Stemphylium leaf blight has been considered a minor foliar disease as it has not done much damage in New York since the early 1990s.

Read More: Disease News and Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.